Descriptive Observational Study ALK-2016-CPHG

Clinical trial NCT03718117 · COMPLETED

Trial details

NCT number: NCT03718117
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

NSCLC Crizotinib ALK Gene Rearrangement or ROS1 Gene Rearrangement

Start date: 2017-01-03
Primary completion: 2020-07-01
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.